

**ADVANCES IN THE USE OF  
BIOMARKERS IN BIOCHIP AND  
MICROARRAY TESTING**  
Innovative technologies, growth  
opportunities and the future market  
outlook

*By Biophoenix*

## **Biophoenix**

Biophoenix is a biomedical consultancy based in the heart of England, UK, which was founded by Dr Sreten Bogdanovic and Dr Beata Langlands. Established with support from the UK Department of Trade and Industry (DTI) in 1994, Biophoenix provides detailed, accurate, market and technical information to support decision-making by biotechnology-based enterprises in the healthcare industry. In doing so, Biophoenix relies on its comprehensive in-house bioindustry database and a wide network of contacts. Biophoenix also audits biotechnology-based enterprises with regard to the risk of intellectual property litigation on behalf of several Lloyds of London insurers. Further information is available on the internet at [www.biophoenix.com](http://www.biophoenix.com).

Dr Bogdanovic is Managing Director of Biophoenix. He holds a PhD in endocrinology from Imperial College, UK, and has worked as product manager for immunodiagnostics with the UK subsidiary of Boehringer Mannheim (now owned by Roche), and as an independent biomedical market analyst with Cistron, UK. Dr Langlands holds a PhD in biochemistry from the University of Glasgow, UK, and has worked as an immunologist, a project leader with a new biotechnology company based at Warwick University in the UK, and as a university lecturer. Biophoenix has researched and written over 50 in-depth management/market reports.

Copyright © 2009 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

# Table of Contents

## Advances in the use of biomarkers in biochip and microarray testing

### **Executive Summary 12**

<b>Biochips, biomarkers, and in vitro diagnostics</b>	<b>12</b>
<b>DNA microarrays</b>	<b>13</b>
<b>Protein microarrays</b>	<b>14</b>
<b>Tissue and cell microarrays</b>	<b>16</b>
<b>Lab-on-a-Chip technologies</b>	<b>17</b>
<b>Biochip companies</b>	<b>18</b>
<b>Market Analysis and Forecasts</b>	<b>18</b>

### **Chapter 1 Biochips, biomarkers, and in vitro diagnostics 22**

<b>Summary</b>	<b>22</b>
<b>Biomarker-based IVDs</b>	<b>23</b>
<b>Introduction to biochips</b>	<b>23</b>
Microarrays	23
Microfluidic chips	24
<b>Background on nucleic acid and protein testing</b>	<b>25</b>
Immunoassay technology	25
Immunoassay formats	26
Rapid immunochromatographic assays	28
Multiplexed assays	28
Nucleic acid testing	29
Probe-based NAT	30
Amplification technologies	32
<b>Biomarker discovery and validation</b>	<b>33</b>
<b>Translating biomarkers into IVDs</b>	<b>35</b>
<b>Regulation of <i>in vitro</i> diagnostics</b>	<b>36</b>
Europe	37

USA		37
	Draft guidance on multivariate analysis	40
<b>Chapter 2</b>	<b>DNA microarrays</b>	<b>44</b>
	<b>Summary</b>	<b>44</b>
	<b>Introduction</b>	<b>46</b>
	<b>DNA microarray fabrication technologies</b>	<b>49</b>
	Standard microarrays	49
	3-D DNA microarrays	53
	Particle (bead)-based microarrays	54
	<b>Analytical uses of DNA microarrays</b>	<b>56</b>
	SNP genotyping	56
	Detection of genetic imbalances	57
	Gene expression profiling	59
	Single-channel microarrays	60
	Two-channel microarrays	62
	Methods utilizing RT-PCR	64
	MicroRNA expression profiling	65
	<b>Limitations and barriers to commercialization</b>	<b>66</b>
	<b>Key commercial players</b>	<b>69</b>
	<b>DNA microarray testing in cancer</b>	<b>70</b>
	Overview	71
	Progress in breast cancer	74
	Early detection	74
	Classification, prognosis, and treatment	75
	Tumors of unidentified origin	79
	Other advances	80
	<b>DNA microarray testing in genetic disorders</b>	<b>82</b>
	<b>Microarrays testing for adverse drug reactions</b>	<b>86</b>
	<b>DNA microarray testing in transplant management</b>	<b>87</b>
	<b>DNA microarray testing in other conditions</b>	<b>88</b>
	<b>Expanding applications</b>	<b>91</b>
<b>Chapter 3</b>	<b>Protein microarrays</b>	<b>94</b>
	<b>Summary</b>	<b>94</b>
	<b>Introduction</b>	<b>96</b>
	<b>Background on proteomics</b>	<b>97</b>
	<b>Protein microarray technologies</b>	<b>100</b>

Formats	102
Glass slides	102
Microwell/nanowell chips	103
Implementation	103
3.3.2.1 Forward-phase microarrays	103
Prospects for multiplex ELISAs	104
Reverse-phase microarrays	105
Detection of bound targets	106
SELDI ProteinChip technology	107
Fabrication technologies	109
Dispensing technology	109
Protein immobilization strategies	110
Surface chemistries	111
<b>Analytical uses of protein microarrays</b>	<b>113</b>
<b>Commercial microarrays for clinical research</b>	<b>114</b>
<b>Protein microarray diagnostics in cancer</b>	<b>118</b>

## **Chapter 4            Tissue and cell microarrays            124**

<b>Summary</b>	<b>124</b>
<b>Introduction</b>	<b>125</b>
<b>Tissue microarrays</b>	<b>127</b>
Advantages	127
Construction	128
Sources of tissue	129
Scanning and analysis	130
Companies providing products and services	131
Uses of tissue microarrays	132
Clinical investigations in cancer	134
<b>Initiatives using cell microarrays</b>	<b>135</b>
Overview	135
Examples of diagnostic applications	137

## **Chapter 5            Lab-on-a-Chip Technologies            140**

<b>Summary</b>	<b>140</b>
<b>Introduction to microfluidics</b>	<b>141</b>
<b>Lab-on-a-chip devices</b>	<b>144</b>
Construction methods	145
Companies and technologies	146
<b>Multiplexed particle assays</b>	<b>150</b>
Multiplexing at the microlevel	151
Particle encoding technologies	152



<b>Aushon BioSystems Inc</b>	<b>178</b>
Company description	178
Protein microarrays and services	178
<b>AutoGenomics Inc</b>	<b>179</b>
Company description	179
3-D DNA microarrays for diagnostics	179
<b>Beecher Instruments Inc</b>	<b>180</b>
Company description	180
Tissue microarray products and services	181
<b>BioArray Solutions Ltd</b>	<b>182</b>
Company description	182
Bead-based microfluidic arrays	182
<b>BioDot Inc</b>	<b>183</b>
Company description	183
Protein biochip manufacture	183
<b>Caliper Life Sciences Inc</b>	<b>184</b>
Company description	184
Microfluidic lab-on-a-chip systems	184
<b>CapitalBio Corp</b>	<b>185</b>
Company description	185
Microarray systems and diagnostics	185
<b>CombiMatrix Corp</b>	<b>187</b>
Company description	187
DNA microarray technology and diagnostics	188
<b>Cybrdi Inc</b>	<b>190</b>
Company description	190
Tissue microarray products and services	190
<b>Decision Biomarkers Inc</b>	<b>191</b>
Company description	191
Microarrays for multiplex immunoassays	191
<b>Epigenomics AG</b>	<b>192</b>
Company description	192
Methylation microarrays for diagnostics	192
<b>ExonHit Therapeutics SA</b>	<b>193</b>
Company description	193
Differential gene expression profiling	194
<b>Expression Analysis Inc</b>	<b>195</b>
Company description	195
DNA microarray-based testing services	195
<b>GeneNews Ltd</b>	<b>196</b>
Company description	196
Gene expression diagnostics	196
<b>GenTel BioSciences Inc</b>	<b>197</b>
Company description	197
Protein microarrays and research kits	197

<b>Illumina Inc</b>	<b>199</b>
Company description	199
Bead-based microarrays	199
<b>Imgenex Corp</b>	<b>200</b>
Company description	200
Tissue microarrays	201
<b>Iris BioTechnologies Inc</b>	<b>201</b>
Company description	201
DNA microarrays for diagnostic profiling	201
<b>LC Sciences LLC</b>	<b>203</b>
Company description	203
Microarray products and services	203
<b>Life Technologies Corp</b>	<b>204</b>
Company description	204
Microarray/microfluidic research tools	204
<b>Luminex Corp</b>	<b>205</b>
Company description	205
Bead suspension microarrays and diagnostics	205
<b>Maxwell Sensors Inc</b>	<b>207</b>
Company description	207
Microarray and microfluidic products	207
<b>Med BioGene Inc</b>	<b>208</b>
Company description	208
Gene expression microarrays for diagnosis	208
<b>Micronics Inc</b>	<b>209</b>
Company description	209
Disposable microfluidic diagnostic labcards	209
<b>Micronit Microfluidics BV</b>	<b>210</b>
Company description	210
Microfluidic glass chips	211
<b>Oxford Gene Technology Ltd</b>	<b>211</b>
Company description	211
DNA and protein microarrays	212
<b>Protein BioTechnologies Inc</b>	<b>212</b>
Company description	212
Protein and tissue microarrays	212
<b>Response Genetics Inc</b>	<b>213</b>
Company description	213
Microarray gene expression cancer testing	213
<b>Roche NimbleGen Inc</b>	<b>214</b>
Company description	214
DNA microarray products and services	215
<b>SABiosciences Corp</b>	<b>217</b>
Company description	217
DNA microarrays and RT-PCR arrays	217

<b>Signature Genomic Laboratories LLC</b>	<b>218</b>
Company description	218
Microarray-based cytogenetic diagnostics	218
<b>SomaLogic Inc</b>	<b>219</b>
Company description	219
Aptamer microarrays	219
<b>US Biomax Inc</b>	<b>220</b>
Company description	220
Tissue microarrays	220
<b>Xceed Molecular Corp</b>	<b>221</b>
Company description	221
3-D DNA microarrays	222
<b>Chapter 7</b>	<b>Market analysis and forecasts</b>
	<b>224</b>
<b>Summary</b>	<b>224</b>
<b>Introduction</b>	<b>225</b>
<b>DNA microarray review</b>	<b>226</b>
Market history	226
Some leading players	228
Market growth	230
<b>Protein microarray review</b>	<b>232</b>
Market history	232
Some leading players	234
Market growth	235
<b>Market segmentation and forecasts</b>	<b>235</b>
<b>Market prospects</b>	<b>241</b>
<b>Chapter 8</b>	<b>Appendix 1 Abbreviations and Acronyms</b>
	<b>246</b>
<b>Scientific/technical/medical terms</b>	<b>246</b>
<b>A2.2 Institutional/regulatory terms</b>	<b>247</b>
<b>Chapter 9</b>	<b>Appendix 2 Research Methodology</b>
	<b>250</b>
<b>Index</b>	<b>251</b>

# List of Figures

Figure 1.1:	Non-competitive “sandwich” assay	27
Figure 2.2:	An approx 18,000-test gene microarray	46
Figure 3.3:	Principle of a spatially addressable protein microarray	106

# List of Tables

Table 2.1:	Companies featured in Chapter 2	48
Table 2.2:	DNA microarray technologies/products	49
Table 2.3:	Systems for gene expression profiling	59
Table 2.4:	Gene expression tests in breast cancer	70
Table 2.5:	Other cancer tests	71
Table 2.6:	DNA microarray testing in genetic disorders	82
Table 3.7:	Companies featured in Chapter 3	97
Table 3.8:	Protein microarray technologies/products	102
Table 3.9:	Protein microarrays for clinical research	114
Table 3.10:	Protein microarray-enabled cancer diagnostic discovery	118
Table 4.11:	Companies and products featured in Chapter 4	126
Table 5.12:	Companies and products featured in Chapter 5	143
Table 7.13:	Microarray Industry Bibliometric Output, 2000-2008	231
Table 7.14:	Snapshot of FDA approved in vitro diagnostic microarray products	237
Table 7.15:	Microarray Forecasts (\$m)	240
Table 7.16:	Leading Company Market Shares	241